> Contact us

Watch video

IMPLEMENTING REAL-TIME MONITORING AND MAKING IT A SUCCESS STORY

There are several success stories on how real-time monitoring has saved high value products and ensured drug availability. However, Niclas Ohlsson, CEO at TSS, believes companies need to carefully assess and plan before deciding to implement real-time monitoring in their life science supply chains.

Scroll to read on 

I

In the TSS real-time application you can follow your most valuable shipments live, all the way to the last mile. Although this type of application opens up for huge possibilities, it is important to remember that it also requires companies to think through how the organisation and its processes are affected.


This typically calls for an escalation process as well as an organization that is available 24/7, with a global operation team that can, if needed, interact and initiate corrective actions. In the complex eco system of a supply chain, that may involve different companies, experts need to be accessible and actionable.

The first impact of implementing real-time monitoring is the need for a control tower. This control tower must be able to capture all alarms, to be qualified to interpret them, and to conclude what action is suitable, and by whom

Before deciding to implement real-time monitoring, you need to ask yourself: is there a risk that we turn our organization into a reactive rather than a proactive organization? And what is the cost for that?

Niclas Ohlsson says, that, in order to assess the possible effectiveness of real-time monitoring, the supply chain’s white and dark spaces need to be identified. Depending on how your supply chain has been set up, it is important to map areas where possible actions can be taken, but also where it can not be. This information should be mapped against historical data where issues are typically initiated or escalating.


“If there is a high positive overlap, the analysis should assess the causes for the deviation. Knowing this, you need to assess how such a situation can be addressed in the field - which action is required?”


The percentage of cases that could be addressed, and the cost for these real time actions, should then be compared with a proactive action that could alternatively resolve the issue.

To make sure your real-time monitoring experience becomes a success stories, it is crucial that you know which questions to ask during the evaluation process, and what to expect from the vendor. 

> Download TSS’ buyer’s guide to real-time temperature monitoring to learn more!

Go to article: Home | Gut InstinctGo to article: In this issueGo to article: TSS Company InsightGo to article: TSS ABGo to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: ContentsGo to article: Daiichi JitsugyoGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: The Pharma Industry BriefingGo to article: Komtur PharmaceuticalsGo to article: Komtur Pharmaceuticals Company InsightGo to article: How will the UK’s relaxed cannabis regulations impact clinical practice?Go to article: Finnair CargoGo to article: Finnair Cargo | Company InsightGo to article: Developing a new class of cancer combo drugsGo to article: Phoenix Company InsightGo to article: PhoenixGo to article: Antidepressants in the environment: combatting pharmaceutical pollutionGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Christensella: the key to unlocking gut microbiome-based drug discovery?Go to article: CBDepotGo to article: CBDepot Company InsightGo to article: Going digital to improve clinical trial enrolmentGo to article: BEAGo to article: Incretin combination therapy: a breakthrough for type 2 diabetes?Go to article: AlpexGo to article: Ebola in the DRC: vaccinating in a conflict zoneGo to article: Hemp IndustriesGo to article: Unither PharmaceuticalsGo to article: Data overload: turning challenges into opportunities in clinical trialsGo to article: ZenatekGo to article: Solving clinical research challenges: an IT perspectiveGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: EventsGo to article: In the next issue